We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead Sciences sold its experimental drug momelotinib to Sierra Oncology for an upfront fee of $3 million, as well as potential milestone payments of up to $195 million, the latter company announced Wednesday.